These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 23980151)

  • 1. Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains.
    Sha F; Gencer EB; Georgeon S; Koide A; Yasui N; Koide S; Hantschel O
    Proc Natl Acad Sci U S A; 2013 Sep; 110(37):14924-9. PubMed ID: 23980151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface.
    Wojcik J; Lamontanara AJ; Grabe G; Koide A; Akin L; Gerig B; Hantschel O; Koide S
    J Biol Chem; 2016 Apr; 291(16):8836-47. PubMed ID: 26912659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determining folding and binding properties of the C-terminal SH2 domain of SHP2.
    Nardella C; Malagrinò F; Pagano L; Rinaldo S; Gianni S; Toto A
    Protein Sci; 2021 Dec; 30(12):2385-2395. PubMed ID: 34605082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SHP2 is required for BCR-ABL1-induced hematologic neoplasia.
    Gu S; Sayad A; Chan G; Yang W; Lu Z; Virtanen C; Van Etten RA; Neel BG
    Leukemia; 2018 Jan; 32(1):203-213. PubMed ID: 28804122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Targeting of SH2 Domain-Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies.
    Kükenshöner T; Schmit NE; Bouda E; Sha F; Pojer F; Koide A; Seeliger M; Koide S; Hantschel O
    J Mol Biol; 2017 May; 429(9):1364-1380. PubMed ID: 28347651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purification and molecular cloning of SH2- and SH3-containing inositol polyphosphate-5-phosphatase, which is involved in the signaling pathway of granulocyte-macrophage colony-stimulating factor, erythropoietin, and Bcr-Abl.
    Odai H; Sasaki K; Iwamatsu A; Nakamoto T; Ueno H; Yamagata T; Mitani K; Yazaki Y; Hirai H
    Blood; 1997 Apr; 89(8):2745-56. PubMed ID: 9108392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidation of protein interactions necessary for the maintenance of the BCR-ABL signaling complex.
    Gregor T; Bosakova MK; Nita A; Abraham SP; Fafilek B; Cernohorsky NH; Rynes J; Foldynova-Trantirkova S; Zackova D; Mayer J; Trantirek L; Krejci P
    Cell Mol Life Sci; 2020 Oct; 77(19):3885-3903. PubMed ID: 31820037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
    Jain SK; Langdon WY; Varticovski L
    Oncogene; 1997 May; 14(18):2217-28. PubMed ID: 9174058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SH2-containing adapter protein GRB10 interacts with BCR-ABL.
    Bai RY; Jahn T; Schrem S; Munzert G; Weidner KM; Wang JY; Duyster J
    Oncogene; 1998 Aug; 17(8):941-8. PubMed ID: 9747873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.
    Salgia R; Pisick E; Sattler M; Li JL; Uemura N; Wong WK; Burky SA; Hirai H; Chen LB; Griffin JD
    J Biol Chem; 1996 Oct; 271(41):25198-203. PubMed ID: 8810278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling of molecular interaction between apoptin, BCR-Abl and CrkL--an alternative approach to conventional rational drug design.
    Panigrahi S; Stetefeld J; Jangamreddy JR; Mandal S; Mandal SK; Los M
    PLoS One; 2012; 7(1):e28395. PubMed ID: 22253690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural Determinants of Phosphopeptide Binding to the N-Terminal Src Homology 2 Domain of the SHP2 Phosphatase.
    Anselmi M; Calligari P; Hub JS; Tartaglia M; Bocchinfuso G; Stella L
    J Chem Inf Model; 2020 Jun; 60(6):3157-3171. PubMed ID: 32395997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.
    Grebien F; Hantschel O; Wojcik J; Kaupe I; Kovacic B; Wyrzucki AM; Gish GD; Cerny-Reiterer S; Koide A; Beug H; Pawson T; Valent P; Koide S; Superti-Furga G
    Cell; 2011 Oct; 147(2):306-19. PubMed ID: 22000011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SH2-containing phosphotyrosine phosphatase Syp is a target of p210bcr-abl tyrosine kinase.
    Tauchi T; Feng GS; Shen R; Song HY; Donner D; Pawson T; Broxmeyer HE
    J Biol Chem; 1994 May; 269(21):15381-7. PubMed ID: 8195176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells.
    Wisniewski D; Strife A; Swendeman S; Erdjument-Bromage H; Geromanos S; Kavanaugh WM; Tempst P; Clarkson B
    Blood; 1999 Apr; 93(8):2707-20. PubMed ID: 10194451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling.
    Li S; Couvillon AD; Brasher BB; Van Etten RA
    EMBO J; 2001 Dec; 20(23):6793-804. PubMed ID: 11726515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
    Peng Z; Luo HW; Yuan Y; Shi J; Huang SF; Li CL; Cao WX; Huang ZG; Feng WL
    Oncol Rep; 2011 May; 25(5):1381-8. PubMed ID: 21369701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation.
    Sha F; Kurosawa K; Glasser E; Ketavarapu G; Albazzaz S; Koide A; Koide S
    J Mol Biol; 2023 Apr; 435(8):168010. PubMed ID: 36806475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pathogenic T42A mutation in SHP2 rewires the interaction specificity of its N-terminal regulatory domain.
    van Vlimmeren AE; Voleti R; Chartier CA; Jiang Z; Karandur D; Humphries PA; Lo WL; Shah NH
    Proc Natl Acad Sci U S A; 2024 Jul; 121(30):e2407159121. PubMed ID: 39012820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Mechanisms for SHP2 Binding and Activation Are Exploited by Geographically Distinct Helicobacter pylori CagA Oncoproteins.
    Hayashi T; Senda M; Suzuki N; Nishikawa H; Ben C; Tang C; Nagase L; Inoue K; Senda T; Hatakeyama M
    Cell Rep; 2017 Sep; 20(12):2876-2890. PubMed ID: 28930683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.